Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDMA-Assisted Therapy for Pathological Narcissism
NCT06565494Phase 1Active, not recruiting
- Sponsor
- University of Washington
- Start
- Aug 2024
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of midomafetamine in Narcissistic personality disorder (NPD), sponsored by University of Washington. Primary endpoint: Pathological Narcissism Inventory at 9 months. Started Aug 2024; status: active, not recruiting.
02
Drugs
midomafetamine
03
Conditions
Narcissistic personality disorder (NPD)
Beyond the preview
Go deeper on NCT06565494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06565494.